A meta-analysis conducted by Luo et al. (43) put forward that patients with severe COVID-19 benefit more from the CCP transfusion; so we conducted the subanalysis and we found that there was a significantly lower 28-day mortality rate in the severe and critical patients treated with CP compared with the control groups (41/276 vs. 47/199, P = 0.02, OR 0.58 95% CI 0.36–0.93). This evidence concerns the gene CP and COVID-19.